Blockade of EP4 by ASP7657 Modulates Myeloid Cell Differentiation In Vivo and Enhances the Antitumor Effect of Radiotherapy
BioMed Research International · 2023-01 · 2023 (1)
DOI: 10.1155/2023/7133726 ↗Kurz gefasst
Fachartikel in der Zeitschrift BioMed Research International, online erschienen am 28.11.2023. Verfasst von Toshihide Nishibata und 7 weiteren Autor:innen. Beteiligte Einrichtung: Immuno-oncology, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba, Ibaraki 305-8585, Japan. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Astellas Pharma.
Abstract (Originalsprache)
The tumor microenvironment (TME) is thought to influence the antitumor efficacy of immuno‐oncology agents through various products of both tumor and stromal cells. One immune‐suppressive factor is prostaglandin E 2 (PGE 2 ), a lipid mediator whose biosynthesis is regulated by ubiquitously expressed cyclooxygenase‐ (COX‐) 1 and inducible COX‐2. By activating its receptors, PGE 2 induces immune suppression to modulate differentiation of myeloid cells into myeloid‐derived suppressor cells (MDSCs) rather than dendritic cells (DCs). Pharmacological blockade of prostaglandin E receptor 4 (EP4) causes a decrease in MDSCs, reprogramming of macrophage polarization, and increase in tumor‐infiltrated T cells, leading to enhancement of antitumor immunity in preclinical models. Here, we report the effects of the highly potent EP4 antagonist ASP7657 on the DC population in tumor and antitumor immune activation in an immunocompetent mouse tumor model. Oral administration of ASP7657 inhibited tumor growth, which was accompanied by an increase in intratumor DC and CD8 + T cell populations and a decrease in the M‐MDSC population in a CT26 immunocompetent mouse model. The antitumor activity of ASP7657 was dependent on CD8 + T cells and enhanced when combined with an antiprogrammed cell death‐1 (PD‐1) antibody. Notably, ASP7657 also significantly enhanced the antitumor efficacy of radiotherapy in an anti‐PD‐1 antibody refractory model. These results indicate that the therapeutic potential of ASP7657 arises via upregulation of DCs and subsequent CD8 + T cell activation in addition to suppression of MDSCs in mouse models and that combining EP4 antagonists with radiotherapy or an anti‐PD‐1 antibody can improve antitumor efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Immuno-oncology, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba, Ibaraki 305-8585, Japan.
ORCID-Profile: Toshihide Nishibata, Tomoko Kawashima
Förderung
- Astellas Pharma
Zitieren
APA
Nishibata, T., Amino, N., Tanaka-Kado, R., Tsujimoto, S., Kawashima, T., Konagai, S., Suzuki, T., & Takeuchi, M. (2023). Blockade of EP4 by ASP7657 Modulates Myeloid Cell Differentiation In Vivo and Enhances the Antitumor Effect of Radiotherapy. BioMed Research International, 2023(1). https://doi.org/10.1155/2023/7133726
Vancouver
Nishibata T, Amino N, Tanaka-Kado R, Tsujimoto S, Kawashima T, Konagai S, et al. Blockade of EP4 by ASP7657 Modulates Myeloid Cell Differentiation In Vivo and Enhances the Antitumor Effect of Radiotherapy. BioMed Research International. 2023;2023(1). doi:10.1155/2023/7133726
BibTeX
@article{Nishibata2023,
author = {Nishibata, Toshihide and Amino, Nobuaki and Tanaka-Kado, Ruriko and Tsujimoto, Susumu and Kawashima, Tomoko and Konagai, Satoshi and Suzuki, Tomoyuki and Takeuchi, Masahiro},
title = {Blockade of EP4 by ASP7657 Modulates Myeloid Cell Differentiation In Vivo and Enhances the Antitumor Effect of Radiotherapy},
journal = {BioMed Research International},
year = {2023},
volume = {2023},
number = {1},
doi = {10.1155/2023/7133726}
}
EUVIMED